Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

MIRM Mirum Pharmaceuticals Inc

24,07

-0,68 (-2,75%)

18 Mai 2024 - Fermé

Retardé de 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Mirum Pharmaceuticals (NASDAQ:MIRM)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Plus de graphiques de la Bourse Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ:MIRM)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024

Plus de graphiques de la Bourse Mirum Pharmaceuticals

Actualités Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
Samedi 18 Mai 2024 ( il y a 7 heures) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Jeudi 16 Mai 2024 ( il y a 2 jours) • Edgar (US Regulatory)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Samedi 11 Mai 2024 ( il y a 1 semaine) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercredi 8 Mai 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form 8-K - Current report
Mercredi 8 Mai 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Mercredi 8 Mai 2024 ( il y a 1 semaine) • Business Wire

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Mardi 7 Mai 2024 ( il y a 2 semaines) • Business Wire

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
Mardi 7 Mai 2024 ( il y a 2 semaines) • Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Mercredi 1 Mai 2024 ( il y a 2 semaines) • Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jeudi 11 Avril 2024 ( il y a 1 mois) • Business Wire

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Mardi 2 Avril 2024 ( il y a 2 mois) • Business Wire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Lundi 25 Mars 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Plus d'articles sur Mirum Pharmaceuticals Inc

US Global Nanospace (CE)

Nextgen Communications a...

Direct Equity (CE)

CoastalSouth Bancshares (QX)

PowerTrade Fuel Token

Conc do Aeroporto Intern...

Hartford Disciplined Us ...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales